Detalle Publicación

ARTÍCULO

Gasdermin B expression predicts poor clinical outcome in HER2-positive breast cancer

Autores: Hergueta-Redondo, Marta; Sarrio, David; Molina-Crespo, Angela; Vicario, Rocio; Bernado-Morales, Cristina; Martinez, Lidia; Rojo-Sebastian, Alejandro; Serra-Musach, Jordi; Mota, Alba; Martinez-Ramirez, Angel; Angeles Castilla, Ma; González Martín, Antonio; Pernas, Sonia; Cano, Amparo; Cortes, Javier; Nuciforo, Paolo G.; Peg, Vicente; Palacios, Jose; Angel Pujana, Miguel; Arribas, Joaquin; Moreno-Bueno, Gema
Título de la revista: ONCOTARGET
ISSN: 1949-2553
Volumen: 7
Número: 35
Páginas: 56295-56308
Fecha de publicación: 2016
Resumen:
Importantly, GSDMB expression promotes survival to trastuzumab in different HER2-positive breast carcinoma cells, and is associated with trastuzumab resistance phenotype in vivo in Patient Derived Xenografts. In summary, our data identifies the ERBB2 co-amplified and co-expressed gene GSDMB as a critical determinant of poor prognosis and therapeutic response in HER2-positive breast cancer.
DOI: https://doi.org/10.18632/oncotarget.10787.
Impacto:
Google Scholar